Literature DB >> 18622690

CK2alpha/CK1alpha chimeras are sensitive to regulation by the CK2beta subunit.

Ana Jedlicki1, Catherine C Allende, Jorge E Allende.   

Abstract

The effect of CK2beta on the activity of CK2alpha and other protein kinases that can bind this regulatory subunit is not fully understood. In an attempt to improve our understanding of this effect, chimeras of CK2alpha and CK1alpha have been constructed. These chimeras contain different portions of the CK2alpha amino terminal region that are involved in the interaction with CK2beta to form CK2 tetramers. In the case of chimeras 1 and 2, the portions of CK2alpha replace the corresponding segments of CK1alpha. In the case of chimera 3, the fragment of CK2alpha is added to the whole CK1alpha molecule with the exception of the initial methionine. Chimera 3 has 8% of the activity of CK1alphaWT, while chimeras 1 and 2 are 3 orders of magnitude less active than CK1alphaWT. All three chimeras bind tightly to CK2beta, but only chimeras 1 and 2 are significantly stimulated in their capacity to phosphorylate casein and canonical peptide substrates by addition of the regulatory subunit. No stimulation was observed with phosvitin or non-canonical peptides derived from beta-catenin. CK2beta protects chimeras 1 and 2 from thermal inactivation. Chimera 2 can phosphorylate CK2beta and autophosphorylate; however, salt concentrations above 150 mM NaCl eliminate the phosphorylation of CK2beta but not the autophosphorylation of chimera 2. Similarly, high salt decrease the stimulatory effect of CK2beta on the phosphorylation of casein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18622690     DOI: 10.1007/s11010-008-9825-2

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  32 in total

Review 1.  Protein kinase CK2 and its role in cellular proliferation, development and pathology.

Authors:  B Guerra; O G Issinger
Journal:  Electrophoresis       Date:  1999-02       Impact factor: 3.535

2.  CK2 beta, which inhibits Mos function, binds to a discrete domain in the N-terminus of Mos.

Authors:  Soyan L Lieberman; Joan V Ruderman
Journal:  Dev Biol       Date:  2004-04-15       Impact factor: 3.582

3.  Mechanistic studies of the mitotic activation of Mos.

Authors:  Jianbo Yue; James E Ferrell
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

Review 4.  Protein kinase CK2: a challenge to canons.

Authors:  Lorenzo A Pinna
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

5.  Reconstitution of normal and hyperactivated forms of casein kinase-2 by variably mutated beta-subunits.

Authors:  B Boldyreff; F Meggio; L A Pinna; O G Issinger
Journal:  Biochemistry       Date:  1993-11-30       Impact factor: 3.162

6.  Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities.

Authors:  Y Liu; L A Witucki; K Shah; A C Bishop; K M Shokat
Journal:  Biochemistry       Date:  2000-11-28       Impact factor: 3.162

7.  The cDNAs coding for the alpha- and beta-subunits of Xenopus laevis casein kinase II.

Authors:  A Jedlicki; M V Hinrichs; C C Allende; J E Allende
Journal:  FEBS Lett       Date:  1992-02-10       Impact factor: 4.124

8.  A noncanonical sequence phosphorylated by casein kinase 1 in beta-catenin may play a role in casein kinase 1 targeting of important signaling proteins.

Authors:  Oriano Marin; Victor H Bustos; Luca Cesaro; Flavio Meggio; Mario A Pagano; Marcelo Antonelli; Catherine C Allende; Lorenzo A Pinna; Jorge E Allende
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-18       Impact factor: 11.205

Review 9.  Mechanisms of regulating the Raf kinase family.

Authors:  Huira Chong; Haris G Vikis; Kun-Liang Guan
Journal:  Cell Signal       Date:  2003-05       Impact factor: 4.315

10.  Modulation of human checkpoint kinase Chk1 by the regulatory beta-subunit of protein kinase CK2.

Authors:  Barbara Guerra; Olaf-Georg Issinger; Jean Y J Wang
Journal:  Oncogene       Date:  2003-08-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.